Gamida Cell Reports Preliminary Data From Phase 1 Study Of Natural Killer Cell Therapy Candidate GDA-201
Portfolio Pulse from Benzinga Newsdesk
Gamida Cell Ltd. (NASDAQ:GMDA) has reported preliminary data from its Phase 1 study of natural killer (NK) cell therapy candidate GDA-201, showing promising early evidence of anti-tumor activity in patients with relapsed/refractory B cell non-Hodgkin lymphoma. The study is designed to evaluate safety and determine the maximum tolerated dose. The company expects full data readout of the Phase 1 study in Q1 2024.
October 16, 2023 | 8:39 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Gamida Cell's preliminary data from its Phase 1 study of GDA-201 shows promising anti-tumor activity. This could potentially boost investor confidence in the company's research and development capabilities.
The preliminary data from Gamida Cell's Phase 1 study of GDA-201 shows promising anti-tumor activity. This positive news could potentially boost investor confidence in the company's research and development capabilities, leading to a potential increase in the company's stock price in the short term.
CONFIDENCE 85
IMPORTANCE 80
RELEVANCE 100